Preprint Case Report Version 1 Preserved in Portico This version is not peer-reviewed

Efficacy of Double Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases

Version 1 : Received: 31 August 2020 / Approved: 1 September 2020 / Online: 1 September 2020 (11:30:52 CEST)

How to cite: Horowitz, R.; R. Freeman, P. Efficacy of Double Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases. Preprints 2020, 2020090009 (doi: 10.20944/preprints202009.0009.v1). Horowitz, R.; R. Freeman, P. Efficacy of Double Dose Dapsone Combination Therapy in the Treatment of Chronic Lyme Disease/Post-Treatment Lyme Disease Syndrome (PTLDS) and Associated Co-infections: A Report of Three Cases. Preprints 2020, 2020090009 (doi: 10.20944/preprints202009.0009.v1).

Abstract

Three patients with multi-year histories of relapsing and remitting Lyme disease and associated co-infections despite extended antibiotic therapy were each given double dose dapsone combination therapy (DDD CT) for a total of 7-8 weeks. At the completion of therapy, all three patients major Lyme symptoms remained in remission for a period of 25-30 months. In conclusion, Double dose dapsone therapy could represent a novel and effective anti-infective strategy in chronic Lyme disease/PTLDS, especially in those individuals who have failed regular dose dapsone combination therapy (DDS CT) or standard antibiotic protocols. A randomized, blinded, placebo-controlled trial is warranted to evaluate the efficacy of DDD CT in those individuals with chronic Lyme disease/PTLDS.

Subject Areas

Lyme disease; Post-Treatment Lyme Disease Syndrome (PTLDS); dapsone combination therapy (DDS CT); double dose dapsone combination therapy (DDD CT); babesiosis; persistent infection

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 0
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.